Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Sep;13(17):e70059.
doi: 10.1002/cam4.70059.

Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second-line monotherapy for patients with small-cell lung cancer

Jieran Long  1 , Xuefei Li  2 , Lin Wu  3 , Guohua Yu  4 , Aimin Zang  5 , Yanqiu Zhao  6 , Jinsheng Shi  7 , Ligong Nie  8 , Xuan Zhao  9 , Jian Fang  1
Affiliations
Clinical Trial

Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second-line monotherapy for patients with small-cell lung cancer

Jieran Long et al. Cancer Med. 2024 Sep.

Abstract

Purpose: To evaluate the safety, tolerability, and preliminary efficacy of multiple doses of pegylated irinotecan (JK1201I) as a second-line monotherapy for treating small-cell lung cancer (SCLC) patients.

Methods: According to the "3 + 3" dose-escalation principle, patients received intravenous JK1201I at 180 or 220 mg/m2 once every 3 weeks for four cycles. Progression-free survival (PFS), overall survival (OS), median progression-free survival (mPFS), and median overall survival (mOS) were evaluated. The Kaplan-Meier method was used to analyze PFS and overall OS. Brookmeyer and Crowley's method was used for mPFS and mOS.

Results: This study included 29 patients with stage III-IV SCLC (stage IIIa, n = 1; stage IIIb, n = 1; and stage IV, n = 27). Of these, 26 patients were enrolled in the 180 mg/m2 dose group, and 3 patients were enrolled in the 220 mg/m2 dose group. No dose-limiting toxicity (DLT) was noted during the first 28 days of treatment. Grade 3 or higher adverse events were recorded in the 180 mg/m2 group, including diarrhea (11.5%, 3/26), neutropenia (7.7%, 2/26), and leukopenia (7.7%, 2/26). In the 220 mg/m2 group, one patient (33.3%, 1/3) experienced neutropenia or leukopenia. In the 180 mg/m2 group, 38.5% (10/26) of patients achieved an objective response rate (ORR), with a disease control rate (DCR) of 73.1% (19/26). The mPFS and mOS were 3.4 and 12.1 months, respectively. In the 220 mg/m2 group, one patient had stable disease, and one had progressive disease (PD). The ORR, DCR, mPFS, and mOS were 0% (0/3) and 33.3% (1/3), 2.7 months and 2.7 months, respectively.

Conclusion: JK1201I exhibits promising efficacy and relatively low toxicities as a second-line monotherapy for SCLC, warranting further large-scale clinical studies to evaluate its efficacy in greater detail.

Keywords: overall survival; safety; second‐line monotherapy; small‐cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Plasma concentration‐time profiles for JK1201I, free irinotecan, SN‐38, and SN‐38G.
FIGURE 2
FIGURE 2
Estimated progression‐free survival (PFS) of patients under different dosages of JK1021I.
FIGURE 3
FIGURE 3
Estimated overall survival (PFS) of patients under different dosages of JK1021I.
FIGURE 4
FIGURE 4
Best change in the target lesion size from baseline (full analysis set).
FIGURE 5
FIGURE 5
Waterfall plot describing best response and corresponding duration.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Zhong YJ, Wen YF, Wong HM, Yin G, Lin R, Yang SY. Trends and patterns of disparities in burden of lung cancer in the United States, 1974–2015. Front Oncol. 2019;9:404. - PMC - PubMed
    1. Zhang R, Li P, Li Q, et al. Radiotherapy improves the survival of patients with extensive‐disease small‐cell lung cancer: a propensity score matched analysis of surveillance, epidemiology, and end results database. Cancer Manag Res. 2018;10:6525‐6535. - PMC - PubMed
    1. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second‐line treatment of small‐cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of cancer early clinical studies group and new drug development office, and the lung cancer cooperative group. J Clin Oncol. 1997;15(5):2090‐2096. - PubMed
    1. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. J Clin Oncol. 2006;24(34):5441‐5447. - PubMed
    1. Kondo R, Watanabe S, Shoji S, et al. A phase II study of Irinotecan for patients with previously treated small‐cell lung cancer. Oncology. 2018;94(4):223‐232. - PubMed

Publication types

MeSH terms